Long-Term Therapy with the Guanine Nucleoside Analog Penciclovir Controls Chronic Duck Hepatitis B Virus Infection In Vivo | Zendy

Enjarn Lin | Zendy; Carolyn A. Luscombe | Zendy; Danni Colledge | Zendy; Yan Yan Wang | Zendy; Stephen Locarnini | Zendy

Open Access

Long-Term Therapy with the Guanine Nucleoside Analog Penciclovir Controls Chronic Duck Hepatitis B Virus Infection In Vivo

Author(s) -

Enjarn Lin,

Carolyn A. Luscombe,

Danni Colledge,

Yan Yan Wang,

Stephen Locarnini

Publication year - 1998

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.42.8.2132

Subject(s) - penciclovir , virology , nucleoside analogue , duck hepatitis b virus , biology , nucleoside , in vivo , guanine , virus , hepatitis b virus , famciclovir , pharmacology , hepadnaviridae , medicine , biochemistry , gene , nucleotide , microbiology and biotechnology , herpes simplex virus

Ducks congenitally infected with duck hepatitis B virus (DHBV) were treated with the antiviral guanine nucleoside analog penciclovir for 12 or 24 weeks at a dosage of 10 mg/kg of body weight per day. By the completion of both 12 and 24 weeks of therapy, molecular hybridization studies of the liver tissue revealed that the viral DNA, RNA, and protein levels were significantly reduced compared to those in the placebo-treated controls. Penciclovir treatment for 12 or 24 weeks was not associated with any toxicity, establishing the efficacy and safety of long-term penciclovir therapy in chronic DHBV infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research